This pilot clinical trial studies positron emission tomography (PET)-computed tomography (CT) and PET-magnetic resonance imaging (MRI) with fludeoxyglucose F 18 in diagnosing younger patients with cancer. Comparing results of diagnostic procedures may help doctors predict a patient's response to treatment and help plan the best treatment.
Additional locations may be listed on ClinicalTrials.gov for NCT01839747.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVES:
I. To perform a qualitative comparison of image quality between PET-MRI and PET-CT exams being performed on pediatric oncology patients during the same visit.
II. To compare the ability of PET-MRI to determine extent of active malignancy by comparing PET-MRI standardized uptake values (SUV) with PET-CT (fludeoxyglucose F 18) FDG reference.
III. To assess the number of unexpected indeterminate lesions detected on PET-MRI and PET-CT studies requiring additional workup.
OUTLINE:
Patients undergo PET-CT followed by PET-MRI with fludeoxyglucose F 18.
After completion of study, patients are followed up for 12 months.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorMichael Stanley Gee
